Jefferies Starts OncoMed Pharmaceuticals (OMED) at Buy, $27 PT

August 12, 2013 7:21 AM EDT
Get Alerts OMED Hot Sheet
Price: $7.74 +1.44%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade OMED Now!
Join SI Premium – FREE
Jefferies initiates coverage on OncoMed Pharmaceuticals (NASDAQ: OMED) with a Buy. PT $27.00.

Analyst Thomas Wei comments, "OMED is a leader in the science behind cancer stem cells, which are thought to drive progression and metastases, and has generated five clinical stage candidates in Phase 1 trials using its platform, creating multiple opportunities for success in major solid tumors and hematologic malignancies."

For an analyst ratings summary and ratings history on OncoMed Pharmaceuticals click here. For more ratings news on OncoMed Pharmaceuticals click here.

Shares of OncoMed Pharmaceuticals closed at $19.84 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co

Add Your Comment